Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice

Journal of Neural Transmission

Volumn 112, Issue 5, 2005, Pages 613-631

  Diguet, E ^a   Fernagut, P O ^a   Scherfler, C ^b   Wenning, G ^b   Tison, F ^a  

^a CNRS   (France)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

3 nitropropionic acid; Mice; MPTP; Riluzole; Striatonigral degeneration

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROPROPIONIC ACID; RILUZOLE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CELL ACTIVATION; CELL LOSS; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOSE RESPONSE; HISTOPATHOLOGY; INTOXICATION; KINETICS; MACROGLIA; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; OUTCOMES RESEARCH; PERFORMANCE; PRIORITY JOURNAL; ROTAROD TEST; SENSORIMOTOR FUNCTION; STRIATONIGRAL DEGENERATION; TASK PERFORMANCE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NITRO COMPOUNDS; PROPIONIC ACIDS; RILUZOLE;

EID: 17844365354     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0206-z     Document Type: Article

References (76)

1. Albers DS, Beal MF (2002) Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem Int 40: 559-564
2. Alexi T, Hughes PE, Faull RL, Williams CE (1998) 3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. Neuroreport 9: 57-64
3. Araki T, Kumagai T, Tanaka K, Matsubara M, Kato H, Itoyama Y, Imai Y (2001a) Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res 918: 176-181
4. Araki T, Muramatsu Y, Tanaka K, Matsubara M, Imai Y (2001b) Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine) neurotoxicity in mice. Neurosci Lett 312: 50-54
5. Benavides J, Camelin JC, Mitrani N, Flamand F, Uzan A, Legrand JJ, Gueremy C, Le Fur G (1985) 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. II. Biochemical properties. Neuropharmacology 24: 1085-1092
6. Benazzouz A, Boraud T, Dubedat P, Boireau A, Stutzmann JM, Gross C (1995) Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 284: 299-307
7. Benoit E, Escande D (1991) Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch 419: 603-609
8. Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP (1997) Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 48: 384-393
9. th International Congress of Parkinson's Disease and Movement Disorders 2002, Miami, FL, USA. Mov Disord 17: S256 (Abstract)
10. Bezard E, Stutzmann JM, Imbert C, Boraud T, Boireau A, Gross CE (1998a) Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. Eur J Pharmacol 356: 101-104
11. Bezard E, Imbert C, Gross CE (1998b) Experimental models of Parkinson's disease: from the static to the dynamic. Rev Neurosci 9: 71-90
12. Boireau A, Dubedat P, Bordier F, Imperato A, Moussaoui S (2000) The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology 39: 1016-1020
13. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92: 7105-7109
14. Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59: 427-468
15. Bryson HM, Fulton B, Benfield P (1996) Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 52: 549-563
16. Burn DJ, Jaros E (2001) Multiple system atrophy: cellular and molecular pathology. Mol Pathol 54: 419-426
17. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19: 3248-3257
18. Cassarino DS, Bennett JP (1999) An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Rev 29: 1-25
19. Cheramy A, Barbeito L, Godeheu G, Glowinski J (1992) Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 147: 209-212
20. Clarke CE, Lowry M (2000) Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol 7: 661-665
21. Coggeshall RE (1992) A consideration of neural counting methods. Trends Neurosci 15: 9-13
22. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5: 137-143
23. Debono MW, Le Guern J, Canton T, Doble A, Pradier L (1993) Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 235: 283-289
24. Dirson G, Desjardins P, Tannenberg T, Dodd P, Butterworth RF (2002) Selective loss of expression of glutamate GluR2/R3 receptor subunits in cerebellar tissue from a patient with olivopontocerebellar atrophy. Metab Brain Dis 17: 77-82
25. Dulawa SC, Grandy DK, Low MJ, Paulus MP, Geyer MA (1999) Dopamine D4 receptor-knockout mice exhibit reduced exploration of novel stimuli. J Neurosci 19: 9950-9956
26. Fearnley JM, Lees AJ (1990) Striatonigral degeneration. A clinicopathological study. Brain 113: 1823-1842
27. Fernagut PO, Diguet E, Stefanova N, Biran M, Wenning GK, Canioni P, Bioulac B, Tison F (2002a) Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57B1/6 mice: behavioural and histopathological characterisation. Neuroscience 114: 1005-1017
28. Fernagut PO, Diguet E, Jaber M, Bioulac B, Tison F (2002b) Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage. Eur J Neurosci 15: 2053-2056
29. Fernagut PO, Chalon S, Diguet E, Guilloteau D, Tison F, Jaber M (2003) Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience 116: 1123-1130
30. Fernagut PO, Diguet E, Bioulac B, Tison F (2004a) MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration. Exp Neurol 185: 47-62
31. Fernagut PO, Ghorayeb I, Diguet E, Tison F (2004b) In vivo models of Multiple System Atrophy. Mov Disord (in press)
32. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates, 1st edn. Academic Press, New York
33. Gahtan E, Auerbach JM, Groner Y, Segal M (1998) Reversible impairment of long-term potentiation in transgenic Cu/Zn-SOD mice. Eur J Neurosci 10: 538-544
34. Ghorayeb I, Puschban Z, Fernagut PO, Scherfler C, Rouland R, Wenning GK, Tison F (2001) Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. Exp Neurol 167: 133-147
35. Ghorayeb I, Fernagut PO, Hervier L, Labattu B, Bioulac B, Tison F (2002a) A 'single toxin-double lesion' rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis. Neuroscience 115: 533-546
36. Ghorayeb I, Fernagut PO, Stefanova N, Wenning GK, Bioulac B, Tison F (2002b) Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + 3-nitropropionic acid model of striatonigral degeneration in monkeys. Neurosci Lett 335: 34-38
37. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989
38. Gilman S, Low PA, Quinn N, Albanese A, Ben Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Olivier E, Robertson D, Schatz I, Wenning GK (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163: 94-98
39. Goto S, Hirano A, Rojas-Corona RR (1989) An immunohistochemical investigation of the human neostriatum in Huntington's disease. Ann Neurol 25: 298-304
40. Greene JG, Greenamyre JT (1996) Bioenergetics and glutamate excitotoxicity. Prog Neurobiol 48: 613-634
41. Guyot MC, Palfi S, Stutzmann JM, Maziere M, Hantraye P, Brouillet E (1997) Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 81: 141-149
42. Kahle PJ, Neumann M, Ozmen L, Jacobsen H, Spooren W, Fuss B, Mallon B, Macklin WB, Fujiwara H, Hasegawa M, Iwatsubo T, Kretzschmar HA, Haass C (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3: 583-588
43. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y (2002) Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 9: 244-248
44. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A (1998) Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39: 167-180
45. Kuiper MA, Teerlink T, Visser JJ, Bergmans PL, Scheltens P, Wolters EC (2000) L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm 107: 183-189
46. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5: 1403-1409
47. Mary V, Wahl F, Stutzmann JM (1995) Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission. Neurosci Lett 201: 92-96
48. Matsuura K, Kabuto H, Makino H, Ogawa N (1997) Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 73: 45-48
49. Meissner W, Hill MP, Tison F, Gross CE, Bezard E (2004) Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 25: 249-253
50. Mizoule J, Meldrum B, Mazadier M, Croucher M, Ollat C, Uzan A, Legrand JJ, Gueremy C, Le Fur G (1985) 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. I. Anticonvulsant properties. Neuropharmacology 24: 767-773
51. A and glycine receptor channels. Eur J Pharmacol 415: 135-140
52. Noh KM, Hwang JY, Shin HC, Koh JY (2000) A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. Neurobiol Dis 7: 375-383
53. Obinu MC, Reibaud M, Blanchard V, Moussaoui S, Imperato A (2002) Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. Mov Disord 17: 13-19
54. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y (1985) A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50: 435-441
55. Palfi S, Riche D, Brouillet E, Guyot MC, Mary V, Wahl F, Peschanski M, Stutzmann JM, Hantraye P (1997) Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Exp Neurol 146: 135-141
56. Peluffo H, Estevez A, Barbeito L, Stutzmann JM (1997) Riluzole promotes survival of rat motoneurons in vitro by stimulating trophic activity produced by spinal astrocyte monolayers. Neurosci Lett 228: 207-211
57. Probst-Cousin S, Rickert CH, Schmid KW, Gullotta F (1998) Cell death mechanisms in multiple system atrophy. Neuropathol Exp Neurol 57: 814-821
58. Quinn N (1994) Multiple system atrophy. Movement disorders 3. Butterworth, London, pp 256-275
59. Roberts RC, Ahn A, Swartz KJ, Beal MF, DiFiglia M (1993) Intrastriatal injections of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome. Exp Neurol 124: 274-282
60. Scherfler C, Puschban Z, Ghorayeb I, Goebel GP, Tison F, Jellinger K, Poewe W, Wenning GK (2000) Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience 99: 43-54
61. Schulz JB, Henshaw DR, Jenkins BG, Ferrante RJ, Kowall NW, Rosen BR, Beal MF (1994) 3-Acetylpyridine produces age-dependent excitotoxic lesions in rat striatum. J Cereb Blood Flow Metab 14: 1024-1029
62. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30: 171-182
63. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 348-355
64. Simonian NA, Coyle JT (1996) Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 36: 83-106
65. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxida-tive stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275: 18344-18349
66. Stefani A, Spadoni F, Bernardi G (1997) Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147: 115-122
67. Stutzmann JM, Doble A (1994) Blockade of glutamatergic transmission: the strange case of riluzole. In: Jolles G, Stutzmann JM (eds) Neurodegenerative diseases. Academic Press, London, pp 205-214
68. Tison F, Wenning GK, Daniel SE, Quinn N (1995) The pathophysiology of parkinsonism in multiple system atrophy. Eur J Neurol 2: 435-444
69. Wahl F, Renou E, Mary V, Stutzmann JM (1997) Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury. Brain Res 756: 247-255
70. Wang J, Dib M, Lenoir M, Vago P, Eybalin M, Hameg A, Pujol R, Puel JL (2002) Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig. Neuroscience 111: 635-648
71. Wenning GK, Braune S (2001) Multiple system atrophy: pathophysiology and management. CNS Drugs 15: 839-852
72. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP (1994) Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 117: 835-845
73. Wenning GK, Granata R, Puschban Z, Scherfler C, Poewe W (1999) Neural transplantation in animal models of multiple system atrophy: a review. J Neural Transm [Suppl] 55: 103-113
74. Wenning GK, Tison F, Scherfler C, Puschban Z, Waldner R, Granata R, Ghorayeb I, Poewe W (2000) Towards neurotransplantation in multiple system atrophy: clinical rationale, pathophysiological basis, and preliminary experimental evidence. Cell Transplant 9: 279-288
75. Wullner U, Weller M, Kornhuber J, Bornemann A, Schulz JB, Riederer P, Klockgether T (2000) Altered expression of calcium- and apoptosis-regulating proteins in multiple system atrophy Purkinje cells. Mov Disord 15: 269-275
76. Yamashita T, Ando Y, Obayashi K, Terazaki H, Sakashita N, Uchida K, Ohama E, Ando M, Uchino M (2000) Oxidative injury is present in Purkinje cells in patients with olivoponto-cerebellar atrophy. J Neurol Sci 175: 107-110